Navigation Links
Anapol Schwartz Attorney Representing Trasylol(R) Victims Says Medical Study - Confirming Heart Bypass Drug Mortality Risk - to Open Floodgates for More Litigation

PHILADELPHIA, Feb. 20 /PRNewswire/ -- According to Anapol Schwartz ( attorney James Ronca (, a New England Journal of Medicine study ( (to be released in the February 21, 2008, print edition) confirms that Bayer AG's blood-clotting drug Trasylol(R), used in coronary artery bypass graft (CABG) procedures, causes kidney/renal failure and increases mortality risk. While initial findings of the study, commissioned by Bayer, were sent to the drug company and the FDA in 2006, this is the first time the final results have been published in full.

Ronca, who is one of the chairs of the national Trasylol(R) litigation, and represents a dozen families and victims (see Trasylol(R) lawsuit ( and a recent wrongful death complaint ( filed in Philadelphia), argues this study reinforces inherent problems in the FDA's screening process and opens the floodgates for additional litigation.

"According to published sources, thousands may have died from Trasylol(R), when this could have been prevented. Again, we have another example of the FDA not protecting the public -- and the safety of individuals taking a back seat to company profits," says Ronca, who leads advocacy initiatives to raise awareness about Trasylol's(R) side effects.

Pulled by Bayer from the market in November 2007 in response to FDA concerns, Trasylol(R) is administered by an anesthesiologist during CABG surgery ( to limit bleeding. Affected patients typically experience kidney/renal failure symptoms within 48 hours. Many, however, are unaware they have received the drug, complicating diagnosis.

"These findings should further educate the public about Trasylol's(R) dangers, and open the door for victims, and those who don't realize they are victims, to receive remuneration for their injuries," stresses Ronca, who has served as counsel to victims in product liability cases involving Baycol, LOTRONEX, hormone replacement therapy and breast implants.

Anapol, Schwartz, Weiss, Cohan, Feldman & Smalley is a personal injury firm with law offices in Philadelphia, Reading, Media, and Harrisburg, Pa., as well as Cherry Hill, N.J. ( The firm is a multi-faceted practice with a tradition of excellence in medical malpractice law, pharmaceutical mass tort, toxic tort, class actions, products liability, automobile, securities and wrongful termination litigation. Since its founding in 1977, the firm has grown to over 30 attorneys, and compiled a record of success exceptional among its peers.

Contact: Alexandra Kane-Weiss/Jennifer Wasilisin


SOURCE Anapol, Schwartz, Weiss, Cohan, Feldman & Smalley
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Consumer Driven Healthcare Continues To Make Its Mark on Indianapolis Market
2. St.Vincent and Publicis Indianapolis Receive National Service Industry Advertising Awards
3. Brown Mackie College - Indianapolis Announces New Degree Program in Occupational Therapy
4. Community Health Network of Indianapolis Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology
5. Tobacco-Free Kids Indiana Action Fund Launches Campaign in Support of Angela Mansfield and Scott Keller for Indianapolis City-County Council
6. Pennsylvania Attorney General Corbett Announces Multi-State Settlement With Caremark
7. AHIP Statement on New York Attorney Generals Announcement
8. Pennsylvania Attorney General Approves Vincentian Collaborative System-Marian Manor Integration
9. Former FTC Attorney Christine White Joins Crowell & Morings Health Care and Antitrust Groups
10. Elder Care Operator and Plaintiff Attorney Announce Unprecedented Settlement Agreement in Class Action Lawsuit
11. Statement from AAJ President Kathleen Flynn Peterson on ATRAs Latest Attack on Civil Justice Attorneys
Post Your Comments:
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
(Date:10/12/2017)... ... , ... IsoComforter, Inc. ( ), one of the Nation’s ... design of the shoulder pad. The shoulder pad provides optimal support and full ... while using cold therapy. By utilizing ice and water that is circulated from an ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... Washington, D.C. (PRWEB) , ... October 12, 2017 , ... ... of their peers in Washington, D.C., for the 49th Congress of the International ... Ph.D ., Vice President of the Center for Cancer and Blood Disorders ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... (HLA), the nation's first interactive health literacy software tool, and the Cancer Patient ... aspects of cancer patient education, today announce a new strategic alliance. , ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... -- The Rebound mobile app is poised to become a ... of prescription drug addiction. The app empowers users to develop ... down their dosage in a safe, controlled manner while maximizing ... first 100,000 people to sign up will enjoy 3 months ... ...
(Date:9/28/2017)... Sept. 28, 2017 Cohen Veterans Bioscience and ... use of wearable and home sensors for real-time monitoring ... Signal Foundation, a nonprofit organization focused on disruptive health ... an affordable analytical system to record and integrate behavioral, ... ...
(Date:9/27/2017)... Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... its MyDario product is expected to appear on The Dr. Oz Show ... Oz Show airs in your area: ... The nine-time Emmy award-winning, The Dr. Oz Show kicked off ... The segment features ...
Breaking Medicine Technology: